92-43-3
92-43-3
Chemical Structure
Phenidone
- CAS. Nr.: 92-43-3
- Formula:C9H10N2O
- Molecular Weight:162.19
IUPAC Name: 1-phenylpyrazolidin-3-one
InChIKey: CMCWWLVWPDLCRM-UHFFFAOYSA-N
SMILES: O=C1NN(C2=CC=CC=C2)CC1
Biological Activity: Phenidone, an orally active dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), ameliorates rat paralysis in experimental autoimmune encephalomyelitis. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat[1][2]. Phenidone is used as a photographic developer[3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Phenidone | 98.96% | Phenidone, an orally active dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), ameliorates rat paralysis in experimental autoimmune encephalomyelitis. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat. Phenidone is used as a photographic developer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phenidone (Standard) | ≥98% | Phenidone, an orally active dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), ameliorates rat paralysis in experimental autoimmune encephalomyelitis. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat. Phenidone is used as a photographic developer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Moon C, et al. Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes. Brain Res. 2005;1035(2):206-210. [Content Brief]
- [2]. Stern N, et al. The lipoxygenase inhibitor phenidone is a potent hypotensive agent in the spontaneously hypertensive rat. Am J Hypertens. 1993;6(1):52-58. [Content Brief]
- [3]. Petrakiev A, et al. Emission spectral analysis using photographic plates treated with a phenidone developer. Talanta. 1969;16(12):1583-1587. [Content Brief]
